{"nctId":"NCT04414397","briefTitle":"A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple Hollowing in Adult Participants ≥ 22 Years Old","startDateStruct":{"date":"2020-05-28","type":"ACTUAL"},"conditions":["Temple Hollowing"],"count":205,"armGroups":[{"label":"No Treatment then JUVÉDERM® VOLUMA® XC","type":"OTHER","interventionNames":["Device: JUVÉDERM® VOLUMA® XC","Other: No-treatment control"]},{"label":"JUVÉDERM® VOLUMA® XC","type":"EXPERIMENTAL","interventionNames":["Device: JUVÉDERM® VOLUMA® XC"]}],"interventions":[{"name":"JUVÉDERM® VOLUMA® XC","otherNames":[]},{"name":"No-treatment control","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants in general good health\n* Participants seeking improvement of temple hollowing\n\nExclusion Criteria:\n\n* Temple hollowing due to trauma, congenital malformations, or lipodystrophy\n* Temporomandibular joint dysfunction or any other jaw issues\n* Recurrent temporal headaches such as temporal tendinitis migraine\n* Active autoimmune disease\n* History of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), HA products, or Streptococcal protein\n* Prior facial reconstructive surgeries, facelift, or browlift as well as surgeries on the temple area (eg, biopsy)\n* Fat injection or permanent facial implants anywhere in the face\n* Semipermanent soft-tissue filler treatment in the temple or mid-face within 36 months before enrollment\n* Temporary dermal filler injections above the subnasale within 24 months before enrollment\n* Mesotherapy or cosmetic facial procedures above the subnasale within 6 months before enrollment\n* Botulinum toxin treatment above the subnasale within 6 months before enrollment\n* Females who are pregnant, nursing, or planning a pregnancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"22 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With ≥ 1-grade Improvement From Baseline in the Validated Allergan Temple Hollowing Scale (ATHS) Based on Evaluating Investigator (EI) Assessment at Month 3","description":"The Evaluating Investigator assessed the participant's temple hollowing using the 5-point ATHS scale where 0=convex, rounded temple and 4=severe, deeply recessed, sunken appearance. A 1-point decrease from Baseline indicates improvement.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":null},{"groupId":"OG001","value":"80.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant whether or not it is related to the investigational product. The investigator assesses the relationship of each event to the use of the investigational product. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first use of the investigational product.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Score of \"Improved \" or \"Much Improved\" on the Global Aesthetic Improvement Scale (GAIS) for the Temple Area as Assessed by the Evaluating Investigator (EI) at Month 3","description":"The Evaluating Investigator assessed the participant's temple area using the 5-point GAIS where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"83.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Score of \"Improved\" or \"Much Improved\" on the Global Aesthetic Improvement Scale (GAIS) for the Temple Area as Assessed by the Participants at Month 3","description":"Participants assessed their temple area using the 5-point GAIS where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"92.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline on FACE-Q Satisfaction With Facial Appearance Questionnaire at Month 3","description":"The participants responded to each item on the FACE-Q Satisfaction with Facial Appearance questionnaire using a 4-point scale where: 1=Very Dissatisfied, 2=Somewhat Dissatisfied, 3=Somewhat Satisfied, and 4=Very Satisfied. The total score was transformed to a score of 0 (worst) to 100 (best) for comparison. A positive change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"8.90"},{"groupId":"OG001","value":"24.2","spread":"22.32"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 3 on Participants Responses on FACE-Q Satisfaction With Temples Questionnaire","description":"The participants responded to each item on the FACE-Q Satisfaction with Temples questionnaire using a 4-point scale where: 1=Very Dissatisfied, 2=Somewhat Dissatisfied, 3=Somewhat Satisfied, 4=Very Satisfied. The total score was transformed to a score of 0 (worst) to 100 (best) for comparison. A positive change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"14.77"},{"groupId":"OG001","value":"42.7","spread":"26.65"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":59},"commonTop":["HEADACHE","PAIN IN JAW","COVID-19","TRISMUS"]}}}